Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;34(12):2706-2719.
doi: 10.1111/tri.14145. Epub 2021 Nov 11.

ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis

Annelies E de Weerd  1 , Jan A J G van den Brand  2 , Hanneke Bouwsma  3 , Aiko P J de Vries  3 , Ine Ph M M Dooper  2 , Jan-Stephan F Sanders  4 , Maarten H L Christiaans  5 , Franka E van Reekum  6 , Arjan D van Zuilen  6 , Frederike J Bemelman  7 , Azam S Nurmohamed  7 , Madelon van Agteren  1 , Michiel G H Betjes  1 , Margriet F C de Jong  4 , Marije C Baas  2
Affiliations

ABO-incompatible kidney transplantation in perspective of deceased donor transplantation and induction strategies: a propensity-matched analysis

Annelies E de Weerd et al. Transpl Int. 2021 Dec.

Abstract

Kidney transplant candidates are blood group incompatible with roughly one out of three potential living donors. We compared outcomes after ABO-incompatible (ABOi) kidney transplantation with matched ABO-compatible (ABOc) living and deceased donor transplantation and analyzed different induction regimens. We performed a retrospective study with propensity matching and compared patient and death-censored graft survival after ABOi versus ABOc living donor and deceased donor kidney transplantation in a nationwide registry from 2006 till 2019. 296 ABOi were compared with 1184 center and propensity-matched ABOc living donor and 1184 deceased donor recipients (matching: recipient age, sex, blood group, and PRA). Patient survival was better compared with deceased donor [hazard ratio (HR) for death of HR 0.69 (0.49-0.96)] and non-significantly different from ABOc living donor recipients [HR 1.28 (0.90-1.81)]. Rate of graft failure was higher compared with ABOc living donor transplantation [HR 2.63 (1.72-4.01)]. Rejection occurred in 47% of 140 rituximab versus 22% of 50 rituximab/basiliximab, and 4% of 92 alemtuzumab-treated recipients (P < 0.001). ABOi kidney transplantation is superior to deceased donor transplantation. Rejection rate and graft failure are higher compared with matched ABOc living donor transplantation, underscoring the need for further studies into risk stratification and induction therapy [NTR7587, www.trialregister.nl].

Keywords: ABO-incompatible kidney transplantation; alemtuzumab; deceased donor transplantation; living donor transplantation; patient and graft survival; rejection.

PubMed Disclaimer

Conflict of interest statement

Jan AJG van den Brand is part‐time employed by and has stock options for Binnovate Digital Health B.V. Binnovate Digital Health was not involved in the present research. The other authors of this manuscript have no conflicts of interest to disclose as described by Transplant International.

Figures

Figure 1
Figure 1
Composition of the study cohort.
Figure 2
Figure 2
Patient survival and cumulative incidence of graft failure in blood group incompatible (ABOi) kidney transplant recipients compared with matched blood group compatible (ABOc) living and deceased donor kidney transplant recipients. Outcomes for ABOi kidney transplant recipients (n = 296) were compared with propensity‐matched ABOc recipients (n = 1184) from the same centers, with living and with deceased donors. The matching variables included the following: recipient age, peak panel reactive antibody levels, recipient blood group, and recipient sex. Kidney transplant recipients of an ABOi donor are marked in black, recipients with an ABOc living donor are marked in light blue, and recipients with an ABOc deceased donor are marked in red. The dashed lines represent patient survival with a functioning graft, and the solid lines represent kidney graft failure with patient death considered as a competing event.
Figure 3
Figure 3
Patient survival and cumulative incidence of graft failure in blood group incompatible (ABOi) kidney transplant recipients by induction therapy. Outcomes for ABOi kidney transplant recipients were compared according to the different induction regimens: rituximab (n = 146, black), rituximab/basiliximab (n = 50, red), and alemtuzumab (n = 92, light blue). The dashed lines represent patient survival with a functioning graft, and the solid lines represent kidney graft failure with patient death considered as a competing event.
See this image and copyright information in PMC

Comment in

References

    1. Roodnat JI, van de Wetering J, Claas FH, Ijzermans J, Weimar W. Persistently low transplantation rate of ABO blood type O and highly sensitised patients despite alternative transplantation programs. Transpl Int 2012; 25: 987. - PubMed
    1. Tyden G, Kumlien G, Fehrman I. Successful ABO‐incompatible kidney transplantations without splenectomy using antigen‐specific immunoadsorption and rituximab. Transplantation 2003; 76: 730. - PubMed
    1. Tanabe K, Ishida H, Shimizu T, Omoto K, Shirakawa H, Tokumoto T. Evaluation of two different preconditioning regimens for ABO‐incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab‐treated non‐splenectomy preconditioning regimens. Contrib Nephrol 2009; 162: 61. - PubMed
    1. Bentall A, Herrera LP, Cornell LD, et al. Differences in chronic intragraft inflammation between positive crossmatch and ABO‐incompatible kidney transplantation. Transplantation 2014; 98: 1089. - PubMed
    1. Barnett ANR, Manook M, Nagendran M, et al. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int 2014; 27: 187. - PubMed

Substances